German healthcare group Fresenius SE (NYSE:FMS) reportedly said last week that it is in talks with generic drugmaker Akorn Inc. (NSDQ:AKRX) for a potential takeover. Akorn shares jumped 10% to $32.60 on news of the potential bid.
Fresenius said in a statement that there is no guarantee that any deal will happen as a result of its talks with Akorn. The Illinois-based generics maker is valued at about $3.7 billion.
Get the full story at our sister site, Drug Delivery Business News.
The post Report: Fresenius set to buy generics maker Akorn appeared first on MassDevice.
from MassDevice http://ift.tt/2plCj6x
Cap comentari:
Publica un comentari a l'entrada